Achieve Life Sciences (ACHV) Debt to Equity (2016 - 2025)
Achieve Life Sciences (ACHV) has disclosed Debt to Equity for 5 consecutive years, with $0.17 as the latest value for Q4 2025.
- Quarterly Debt to Equity changed N/A to $0.17 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.17 through Dec 2025, changed N/A year-over-year, with the annual reading at $0.17 for FY2025, N/A changed from the prior year.
- Debt to Equity for Q4 2025 was $0.17 at Achieve Life Sciences, up from $0.04 in the prior quarter.
- The five-year high for Debt to Equity was $36.95 in Q1 2023, with the low at -$0.36 in Q4 2023.
- Average Debt to Equity over 4 years is $4.38, with a median of $0.17 recorded in 2025.
- The sharpest move saw Debt to Equity plummeted 118.84% in 2023, then plummeted 66.49% in 2025.
- Achieve Life Sciences' Debt to Equity stood at $1.94 in 2022, then tumbled by 118.84% to -$0.36 in 2023, then surged by 157.1% to $0.21 in 2024, then fell by 17.32% to $0.17 in 2025.
- Per Business Quant, the three most recent readings for ACHV's Debt to Equity are $0.17 (Q4 2025), $0.04 (Q3 2025), and $0.03 (Q2 2025).